Information  X 
Enter a valid email address

4D Pharma PLC Ord 0.25P (DDDD)

Related News

26-May-2020 07:31 AM

4D Pharma reports wider losses on higher R&D costs

Pharmaceutical company 4D Pharma reported wider losses on higher research and development costs. For the year ended 31 December 2019, pre-tax losses widened to £29.4m from £28.4m on-year. The company recorded a revenue of £0.2m. Resear
28-Sep-2018 09:56 AM

4D Pharma reports modest uptick in losses on increased R&D costs

4D Pharma reported Friday a modest uptick in first-half losses on increased research and development costs as the company expanded its clinical programmes. For the six months to 30 June, pre-tax losses widened to £13.17m from £13.00m. Rese
28-Sep-2017 08:13 AM

4D Pharma losses widen

4D Pharma's pre-tax losses rose to £12.99m in the six months to the end of June - up from £5.5m last time. Research and development costs increased to £8.3m - up from £4.1m a year ago. Net assets totalled £75.3m at t
26-May-2017 02:17 PM

All resolutions passed at AGM of 4D pharma

4D pharma has announced that, at the Annual General Meeting held earlier today, all resolutions put to shareholders were passed. At 2:17pm: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was -9p at 306p Story provided by StockMarketWire.com...
06-Mar-2017 09:26 AM

4D confirms 'very promising' results from clinical study

4D pharma has described early clinical results from its MicroDx platform as 'very promising'. MicroDx has been designed to diagnose, stratify and monitor the treatment of patients based on their gut microbiome, the bacteria which colonise th
13-Dec-2016 08:12 AM

4D pharma update on Blautix clinical trial

4D pharma has issued an update on the phase 1 clinical trial of Blautix, its proprietary single strain live biotherapeutic for the treatment of irritable bowel syndrome. IBS is a functional bowel disorder characterised by discomfort, pain and changes in
22-Aug-2016 07:13 AM

4D starts dosing for Thetanix trial

4D pharma has started dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease ('PCD'). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading
10-Jun-2016 07:31 AM

4D pharma clinical study to resume

4D pharma is set to restart its clinical study on Thetanix, its proprietary programme for the treatment of paediatric Crohn's Disease. The company previously reported a precautionary delay in dosing of patients in the Thetanix phase 1 clinical tria
23-May-2016 09:10 AM

4D pharma's Blautix achieves objective in clinical trial

A phase 1 clinical trial of Blautix - 4D pharma's proprietary programme for the treatment of irritable bowel syndrome - has shown it is safe and well tolerated, achieving the primary objective. The trial, involving 56 healthy volunteers and IBS pat
26-Feb-2016 09:20 AM

4D pharma delays dosing for Thetanix trial

4D pharma has decided to delay dosing for the phase 1 trial of Thetanix, its proprietary programme for the treatment of Paediatric Crohn's Disease, which was scheduled to begin on 1 March. It says this is because concerns have come to light at one o
21-Aug-2015 07:27 AM

4D pharma starts dosing in IBS treatment trial

4D pharma has started dosing in a phase 1 clinical trial for the treatment of irritable bowel syndrome (IBS). The clinical trial will assess the safety and tolerability of Blautix in a number of healthy volunteers and individuals with IBS. In addition, c
07-Aug-2015 07:15 AM

4D pharma in research collaboration

4D pharma has entered into a �?¬4.8 million four-year collaboration project with the APC Microbiome Institute (APC) at University College Cork. The focus of the project will be to research the potential applications of live biotherapeutics in relati
05-Jun-2015 07:46 AM

4D pharma posts pre-tax loss

4D pharma posts a pre-tax loss of £2.38m for the period from 10 January 2014 to the end of December. The company was admitted to trading on AIM on 18 February 2014 raising £16.55m and raised £21.5m in a placing on 14 July. Cash, cash equivalents, de
20-May-2015 07:45 AM

4D progress on clinical development programmes

4D pharma - a pharmaceutical company focusing on the development of live biotherapeutics - has issued a research update on its clinical development programmes. The company currently has two programmes progressing towards the clinic, Blautix, for the tre
07-Jan-2015 09:41 AM

4D pharma update on MicroRx platform

4D pharma says its MicroRx platform has identified a number of bacteria that have demonstrated therapeutically relevant effects in pre-clinical models of rheumatoid arthritis, allergic asthma and severe, steroid resistant asthma. The company started wor
05-Jan-2015 07:30 AM

4D pharma update on Blautix research

4D Pharma, a pharmaceutical company focusing on the development of live biotherapeutics, has issued a research update on Blautix for the treatment of irritable bowel syndrome (IBS). 4D has been working towards its goal of bringing new therapeutics to
23-Sep-2014 09:51 AM

4D Pharma is meeting early expectations

4D Pharma (AIM: DDDD), a pharmaceutical company focussing on developing a number of projects targeting important new therapeutic areas, has announced its interim results covering the period from 10th January 2014 (the date of incorporation of 4D) to 30th
02-Sep-2014 09:41 AM

4d pharma to start two clinical trials next year

4D pharma expects clinical studies for its treatments of irritable bowel syndrome and paediatric Crohn's Disease to start in the second quarter of 2015. 4D says that following the recent award of an FDA orphan designation for Rosburix for the treatm
04-Mar-2014 09:48 AM

4d pharma agrees £1m loan for GT Biologics

4d pharma has agreed to provide a convertible loan of £1,000,000 to GT Biologics. The loan - which is exercisable at 4d pharma's discretion - will enable GT Biologics to accelerate the development of its live biotherapeutic candidates. Interest w
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t